Kodiak Sciences Inc. (KOD) 10-Year Financial Performance & Capital Metrics

KOD • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

AboutKodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Show more

Revenue $0
EBITDA -$160M +36.3%
Net Income -$176M +32.4%
EPS (Diluted) -3.35 +32.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -84.7% -14.1%
ROIC -130.69% -87.0%
Debt/Equity 0.47 -31.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-13.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM-12.88%

ROCE

10Y Avg-205.14%

5Y Avg-39.57%

3Y Avg-49.89%

Latest-49.98%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	257K	549K	490K	911K	4.21M	8.71M	11M	25.95M	26.71M
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-257K	-549K	-490K	-911K	-4.21M	-8.71M	-11M	-25.95M	-26.71M
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1.14%	0.11%	-0.86%	-3.62%	-1.07%	-0.26%	-1.36%	-0.03%
Operating Expenses+	17.15M	25.52M	26.37M	48.28M	131.8M	258.34M	330.38M	251.37M	160.14M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.1M	3.5M	7.58M	10.77M	24.41M	41M	62.79M	71.02M	34.05M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	14.05M	22.02M	18.79M	37.51M	107.39M	217.34M	267.59M	206.3M	126.09M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	25K	-1.23M	-4.07M	0	0	0	0	-25.95M	0
Operating Income+	-17.15M	-25.52M	-26.37M	-49.19M	-136.01M	-267.05M	-341.38M	-277.32M	-186.85M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.49%	-0.03%	-0.87%	-1.76%	-0.96%	-0.28%	0.19%	0.33%
EBITDA+	-16.89M	-24.97M	-25.88M	-48.28M	-131.8M	-258.34M	-330.38M	-251.37M	-160.14M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.48%	-0.04%	-0.87%	-1.73%	-0.96%	-0.28%	0.24%	0.36%
D&A (Non-Cash Add-back)	257K	549K	490K	911K	4.21M	8.71M	11M	25.95M	26.71M
EBIT	-17.13M	-26.75M	-35.92M	-47.36M	-133.07M	-266.97M	-333.81M	-260.48M	-176.21M
Net Interest Income+	0	0	0	1.56M	2.88M	276K	7.05M	16.72M	11.15M
Interest Income	0	0	0	1.57M	2.9M	298K	7.07M	16.73M	11.15M
Interest Expense	6K	1.19M	5.52M	8K	25K	22K	18K	13K	0
Other Income/Expense	19K	-2.42M	-15.07M	1.82M	2.91M	61K	7.56M	16.83M	10.64M
Pretax Income+	-17.13M	-27.94M	-41.44M	-47.37M	-133.1M	-266.99M	-333.82M	-260.49M	-176.21M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	31K	-45K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-17.13M	-27.94M	-41.44M	-47.37M	-133.1M	-266.99M	-333.82M	-260.49M	-176.21M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.63%	-0.48%	-0.14%	-1.81%	-1.01%	-0.25%	0.22%	0.32%
Net Income (Continuing)	-17.13M	-27.94M	-41.44M	-47.37M	-133.1M	-266.99M	-333.82M	-260.49M	-176.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.30	-1.05	-1.16	-1.23	-2.91	-5.16	-6.39	-4.97	-3.35
EPS Growth %	-	0.54%	-0.1%	-0.06%	-1.37%	-0.77%	-0.24%	0.22%	0.33%
EPS (Basic)	-2.30	-1.05	-1.16	-1.23	-2.91	-5.16	-6.39	-4.97	-3.35
Diluted Shares Outstanding	7.44M	26.56M	35.87M	37.85M	45.74M	51.79M	52.25M	52.41M	52.58M
Basic Shares Outstanding	7.44M	26.56M	35.87M	37.85M	45.74M	51.79M	52.25M	52.41M	52.58M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.19M	1.59M	90.45M	339.23M	972M	734.81M	486M	289.31M	171.94M
Cash & Short-Term Investments	9.62M	1.4M	88.25M	336.48M	968.97M	731.51M	478.93M	285.51M	168.07M
Cash Only	9.62M	1.4M	88.25M	211.8M	944.4M	731.51M	190.43M	285.51M	168.07M
Short-Term Investments	0	0	0	124.68M	24.58M	0	288.5M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	2.19M	2.75M	0	3.3M	7.07M	3.8M	3.86M
Total Non-Current Assets+	1.92M	1.65M	1.74M	19.64M	95.34M	169.41M	180.62M	190.06M	163.64M
Property, Plant & Equipment	1.78M	1.51M	1.1M	2.79M	78.81M	108.07M	115.75M	175.02M	148.73M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	140K	140K	140K	11.84M	0	6.32M	6.32M	6.32M	6.18M
Other Non-Current Assets	8K	0	503K	5.01M	16.53M	55.01M	58.55M	8.72M	8.73M
Total Assets+	12.11M	3.24M	92.19M	358.87M	1.07B	904.22M	666.63M	479.37M	335.58M
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.73%	27.42%	2.89%	1.97%	-0.15%	-0.26%	-0.28%	-0.3%
Total Current Liabilities+	2.51M	9.16M	4.83M	11.71M	31.42M	64.68M	52.5M	41.73M	25.57M
Accounts Payable	1.07M	3.36M	1.05M	2.62M	8.65M	12.43M	9.13M	13.61M	3.92M
Days Payables Outstanding	1.53K	2.23K	782.14	1.05K	749.95	520.87	302.92	191.43	53.51
Short-Term Debt	0	0	0	434K	0	3.93M	9.93M	9.77M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	84K	-108K	0	5.55M	0	42.13M	27.41M	12.27M	0
Current Ratio	4.06x	0.17x	18.74x	28.97x	30.93x	11.36x	9.26x	6.93x	6.72x
Quick Ratio	4.06x	0.17x	18.74x	28.97x	30.93x	11.36x	9.26x	6.93x	6.72x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	50.69M	62.82M	530K	1.8M	175.17M	176.22M	177.97M	171.86M	159.72M
Long-Term Debt	0	9.97M	0	0	0	99.94M	100M	100M	0
Capital Lease Obligations	103K	0	0	1.5M	75.03M	76.06M	77.81M	71.86M	59.72M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	50.59M	52.85M	530K	295K	100.15M	211K	162K	0	100M
Total Liabilities	53.2M	71.98M	5.36M	13.51M	206.6M	240.9M	230.46M	213.59M	185.29M
Total Debt+	185K	10.08M	0	1.94M	77.4M	179.94M	187.73M	181.63M	70.34M
Net Debt	-9.44M	8.69M	-88.25M	-209.86M	-866.99M	-551.57M	-2.7M	-103.88M	-97.73M
Debt / Equity	-	-	-	0.01x	0.09x	0.27x	0.43x	0.68x	0.47x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-2858.50x	-21.54x	-4.78x	-6148.75x	-5440.28x	-12138.68x	-18965.50x	-21332.38x	-
Total Equity+	-41.08M	-68.74M	86.83M	345.36M	860.75M	663.32M	436.17M	265.78M	150.29M
Equity Growth %	-	-0.67%	2.26%	2.98%	1.49%	-0.23%	-0.34%	-0.39%	-0.43%
Book Value per Share	-5.52	-2.59	2.42	9.12	18.82	12.81	8.35	5.07	2.86
Total Shareholders' Equity	-41.08M	-68.74M	86.83M	345.36M	860.75M	663.32M	436.17M	265.78M	150.29M
Common Stock	1K	1K	4K	5K	5K	5K	5K	5K	5K
Retained Earnings	-41.39M	-69.32M	-110.77M	-158.13M	-291.23M	-558.22M	-892.04M	-1.15B	-1.33B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	10K	53K	0	-1.31M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.05M	-17.66M	-29.03M	-39.15M	-83.43M	-182.27M	-206.46M	-154.18M	-117.32M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.1%	-0.64%	-0.35%	-1.13%	-1.18%	-0.13%	0.25%	0.24%
Net Income	-17.13M	-27.94M	-41.44M	-47.37M	-133.1M	-266.99M	-333.82M	-260.49M	-176.21M
Depreciation & Amortization	257K	549K	490K	911K	4.21M	8.71M	11M	25.95M	26.71M
Stock-Based Compensation	272K	275K	2.67M	6.11M	30.67M	61.38M	0	88.56M	60.21M
Deferred Taxes	0	1.26M	10.17M	0	-51K	0	0	0	0
Other Non-Cash Items	763K	1.16M	5.48M	-241K	49K	198K	104.4M	-840K	355K
Working Capital Changes	556K	7.04M	-6.39M	1.44M	14.79M	14.43M	11.96M	-7.36M	-28.39M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	23K	2.28M	-2.32M	1.57M	5.22M	-2.09M	1.66M	5.6M	-9.69M
Cash from Investing+	-771K	-209K	-581K	-137M	104.83M	-38.8M	-336.51M	249.23M	-755K
Capital Expenditures	-771K	-209K	-581K	-437K	-7M	-63.3M	-47.36M	-41.43M	-400K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-503K	-136.56K	-3.18M	0	616K	290.65K	0
Cash from Financing+	-120K	9.64M	116.47M	299.69M	717.38M	8.18M	1.9M	31K	501K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-58K	-266K	-176K	2.25M	105.85M	8.18M	-49K	-211K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.82M	-17.86M	-29.61M	-39.58M	-90.43M	-245.57M	-253.82M	-195.61M	-117.72M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.06%	-0.66%	-0.34%	-1.28%	-1.72%	-0.03%	0.23%	0.4%
FCF per Share	-2.26	-0.67	-0.83	-1.05	-1.98	-4.74	-4.86	-3.73	-2.24
FCF Conversion (FCF/Net Income)	0.94x	0.63x	0.70x	0.83x	0.63x	0.68x	0.62x	0.59x	0.67x
Interest Paid	0	0	0	0	0	22K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-458.06%	-21.92%	-22.07%	-35.04%	-60.72%	-74.22%	-84.7%
Return on Invested Capital (ROIC)	-	-	-	-55.03%	-157.84%	-379.67%	-93.92%	-69.87%	-130.69%
Debt / Equity	-	-	-	0.01x	0.09x	0.27x	0.43x	0.68x	0.47x
Interest Coverage	-2858.50x	-21.54x	-4.78x	-6148.75x	-5440.28x	-12138.68x	-18965.50x	-21332.38x	-
FCF Conversion	0.94x	0.63x	0.70x	0.83x	0.63x	0.68x	0.62x	0.59x	0.67x

Frequently Asked Questions

Growth & Financials

Kodiak Sciences Inc. (KOD) grew revenue by 0.0% over the past year. Growth has been modest.

Kodiak Sciences Inc. (KOD) reported a net loss of $217.3M for fiscal year 2024.

Dividend & Returns

Kodiak Sciences Inc. (KOD) has a return on equity (ROE) of -84.7%. Negative ROE indicates the company is unprofitable.

Kodiak Sciences Inc. (KOD) had negative free cash flow of $127.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Kodiak Sciences Inc. (KOD) 10-Year Financial Performance & Capital Metrics

KOD • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesOphthalmology & Ocular Diseases

Revenue $0
EBITDA -$160M +36.3%
Net Income -$176M +32.4%
EPS (Diluted) -3.35 +32.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -84.7% -14.1%
ROIC -130.69% -87.0%
Debt/Equity 0.47 -31.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-13.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM-12.88%

ROCE

10Y Avg-205.14%

5Y Avg-39.57%

3Y Avg-49.89%

Latest-49.98%

Peer Comparison

Ophthalmology & Ocular Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KPRXKiora Pharmaceuticals, Inc.	8.05M	2.19	2.52		22.47%	-38.12%	100%	0.00
KALAKALA BIO, Inc.	16.74M	0.60	-0.09		-141.11%	-388.29%		2.62
CLSDClearside Biomedical, Inc.	5.81M	1.11	-0.16	-79.77%	-7.81%
OTLKOutlook Therapeutics, Inc.	33.47M	0.52	-0.29		-25.93%
ADVMAdverum Biotechnologies, Inc.	96.26M	4.36	-0.66	-72.22%	-130.93%	-189.84%		1.30
IRDOpus Genetics, Inc.	143.45M	2.08	-0.97	-42.3%	-466.09%	-11.43%
SKYESkye Bioscience, Inc.	30.87M	0.96	-1.32			-156.01%		0.01
ALDXAldeyra Therapeutics, Inc.	265.32M	4.41	-4.69			-87.71%		0.22

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	257K	549K	490K	911K	4.21M	8.71M	11M	25.95M	26.71M
COGS % of Revenue	-	-	-	-	-	-	-	-	-
Gross Profit+	-257K	-549K	-490K	-911K	-4.21M	-8.71M	-11M	-25.95M	-26.71M
Gross Margin %	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1.14%	0.11%	-0.86%	-3.62%	-1.07%	-0.26%	-1.36%	-0.03%
Operating Expenses+	17.15M	25.52M	26.37M	48.28M	131.8M	258.34M	330.38M	251.37M	160.14M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-
Selling, General & Admin	3.1M	3.5M	7.58M	10.77M	24.41M	41M	62.79M	71.02M	34.05M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-
Research & Development	14.05M	22.02M	18.79M	37.51M	107.39M	217.34M	267.59M	206.3M	126.09M
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	25K	-1.23M	-4.07M	0	0	0	0	-25.95M	0
Operating Income+	-17.15M	-25.52M	-26.37M	-49.19M	-136.01M	-267.05M	-341.38M	-277.32M	-186.85M
Operating Margin %	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.49%	-0.03%	-0.87%	-1.76%	-0.96%	-0.28%	0.19%	0.33%
EBITDA+	-16.89M	-24.97M	-25.88M	-48.28M	-131.8M	-258.34M	-330.38M	-251.37M	-160.14M
EBITDA Margin %	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.48%	-0.04%	-0.87%	-1.73%	-0.96%	-0.28%	0.24%	0.36%
D&A (Non-Cash Add-back)	257K	549K	490K	911K	4.21M	8.71M	11M	25.95M	26.71M
EBIT	-17.13M	-26.75M	-35.92M	-47.36M	-133.07M	-266.97M	-333.81M	-260.48M	-176.21M
Net Interest Income+	0	0	0	1.56M	2.88M	276K	7.05M	16.72M	11.15M
Interest Income	0	0	0	1.57M	2.9M	298K	7.07M	16.73M	11.15M
Interest Expense	6K	1.19M	5.52M	8K	25K	22K	18K	13K	0
Other Income/Expense	19K	-2.42M	-15.07M	1.82M	2.91M	61K	7.56M	16.83M	10.64M
Pretax Income+	-17.13M	-27.94M	-41.44M	-47.37M	-133.1M	-266.99M	-333.82M	-260.49M	-176.21M
Pretax Margin %	-	-	-	-	-	-	-	-	-
Income Tax+	31K	-45K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-17.13M	-27.94M	-41.44M	-47.37M	-133.1M	-266.99M	-333.82M	-260.49M	-176.21M
Net Margin %	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-0.63%	-0.48%	-0.14%	-1.81%	-1.01%	-0.25%	0.22%	0.32%
Net Income (Continuing)	-17.13M	-27.94M	-41.44M	-47.37M	-133.1M	-266.99M	-333.82M	-260.49M	-176.21M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.30	-1.05	-1.16	-1.23	-2.91	-5.16	-6.39	-4.97	-3.35
EPS Growth %	-	0.54%	-0.1%	-0.06%	-1.37%	-0.77%	-0.24%	0.22%	0.33%
EPS (Basic)	-2.30	-1.05	-1.16	-1.23	-2.91	-5.16	-6.39	-4.97	-3.35
Diluted Shares Outstanding	7.44M	26.56M	35.87M	37.85M	45.74M	51.79M	52.25M	52.41M	52.58M
Basic Shares Outstanding	7.44M	26.56M	35.87M	37.85M	45.74M	51.79M	52.25M	52.41M	52.58M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	10.19M	1.59M	90.45M	339.23M	972M	734.81M	486M	289.31M	171.94M
Cash & Short-Term Investments	9.62M	1.4M	88.25M	336.48M	968.97M	731.51M	478.93M	285.51M	168.07M
Cash Only	9.62M	1.4M	88.25M	211.8M	944.4M	731.51M	190.43M	285.51M	168.07M
Short-Term Investments	0	0	0	124.68M	24.58M	0	288.5M	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	2.19M	2.75M	0	3.3M	7.07M	3.8M	3.86M
Total Non-Current Assets+	1.92M	1.65M	1.74M	19.64M	95.34M	169.41M	180.62M	190.06M	163.64M
Property, Plant & Equipment	1.78M	1.51M	1.1M	2.79M	78.81M	108.07M	115.75M	175.02M	148.73M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0
Long-Term Investments	140K	140K	140K	11.84M	0	6.32M	6.32M	6.32M	6.18M
Other Non-Current Assets	8K	0	503K	5.01M	16.53M	55.01M	58.55M	8.72M	8.73M
Total Assets+	12.11M	3.24M	92.19M	358.87M	1.07B	904.22M	666.63M	479.37M	335.58M
Asset Turnover	-	-	-	-	-	-	-	-	-
Asset Growth %	-	-0.73%	27.42%	2.89%	1.97%	-0.15%	-0.26%	-0.28%	-0.3%
Total Current Liabilities+	2.51M	9.16M	4.83M	11.71M	31.42M	64.68M	52.5M	41.73M	25.57M
Accounts Payable	1.07M	3.36M	1.05M	2.62M	8.65M	12.43M	9.13M	13.61M	3.92M
Days Payables Outstanding	1.53K	2.23K	782.14	1.05K	749.95	520.87	302.92	191.43	53.51
Short-Term Debt	0	0	0	434K	0	3.93M	9.93M	9.77M	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	84K	-108K	0	5.55M	0	42.13M	27.41M	12.27M	0
Current Ratio	4.06x	0.17x	18.74x	28.97x	30.93x	11.36x	9.26x	6.93x	6.72x
Quick Ratio	4.06x	0.17x	18.74x	28.97x	30.93x	11.36x	9.26x	6.93x	6.72x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	50.69M	62.82M	530K	1.8M	175.17M	176.22M	177.97M	171.86M	159.72M
Long-Term Debt	0	9.97M	0	0	0	99.94M	100M	100M	0
Capital Lease Obligations	103K	0	0	1.5M	75.03M	76.06M	77.81M	71.86M	59.72M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	50.59M	52.85M	530K	295K	100.15M	211K	162K	0	100M
Total Liabilities	53.2M	71.98M	5.36M	13.51M	206.6M	240.9M	230.46M	213.59M	185.29M
Total Debt+	185K	10.08M	0	1.94M	77.4M	179.94M	187.73M	181.63M	70.34M
Net Debt	-9.44M	8.69M	-88.25M	-209.86M	-866.99M	-551.57M	-2.7M	-103.88M	-97.73M
Debt / Equity	-	-	-	0.01x	0.09x	0.27x	0.43x	0.68x	0.47x
Debt / EBITDA	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-
Interest Coverage	-2858.50x	-21.54x	-4.78x	-6148.75x	-5440.28x	-12138.68x	-18965.50x	-21332.38x	-
Total Equity+	-41.08M	-68.74M	86.83M	345.36M	860.75M	663.32M	436.17M	265.78M	150.29M
Equity Growth %	-	-0.67%	2.26%	2.98%	1.49%	-0.23%	-0.34%	-0.39%	-0.43%
Book Value per Share	-5.52	-2.59	2.42	9.12	18.82	12.81	8.35	5.07	2.86
Total Shareholders' Equity	-41.08M	-68.74M	86.83M	345.36M	860.75M	663.32M	436.17M	265.78M	150.29M
Common Stock	1K	1K	4K	5K	5K	5K	5K	5K	5K
Retained Earnings	-41.39M	-69.32M	-110.77M	-158.13M	-291.23M	-558.22M	-892.04M	-1.15B	-1.33B
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	10K	53K	0	-1.31M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-16.05M	-17.66M	-29.03M	-39.15M	-83.43M	-182.27M	-206.46M	-154.18M	-117.32M
Operating CF Margin %	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.1%	-0.64%	-0.35%	-1.13%	-1.18%	-0.13%	0.25%	0.24%
Net Income	-17.13M	-27.94M	-41.44M	-47.37M	-133.1M	-266.99M	-333.82M	-260.49M	-176.21M
Depreciation & Amortization	257K	549K	490K	911K	4.21M	8.71M	11M	25.95M	26.71M
Stock-Based Compensation	272K	275K	2.67M	6.11M	30.67M	61.38M	0	88.56M	60.21M
Deferred Taxes	0	1.26M	10.17M	0	-51K	0	0	0	0
Other Non-Cash Items	763K	1.16M	5.48M	-241K	49K	198K	104.4M	-840K	355K
Working Capital Changes	556K	7.04M	-6.39M	1.44M	14.79M	14.43M	11.96M	-7.36M	-28.39M
Change in Receivables	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0
Change in Payables	23K	2.28M	-2.32M	1.57M	5.22M	-2.09M	1.66M	5.6M	-9.69M
Cash from Investing+	-771K	-209K	-581K	-137M	104.83M	-38.8M	-336.51M	249.23M	-755K
Capital Expenditures	-771K	-209K	-581K	-437K	-7M	-63.3M	-47.36M	-41.43M	-400K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-
Other Investing	0	0	-503K	-136.56K	-3.18M	0	616K	290.65K	0
Cash from Financing+	-120K	9.64M	116.47M	299.69M	717.38M	8.18M	1.9M	31K	501K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-
Other Financing	-58K	-266K	-176K	2.25M	105.85M	8.18M	-49K	-211K	0
Net Change in Cash	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-16.82M	-17.86M	-29.61M	-39.58M	-90.43M	-245.57M	-253.82M	-195.61M	-117.72M
FCF Margin %	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.06%	-0.66%	-0.34%	-1.28%	-1.72%	-0.03%	0.23%	0.4%
FCF per Share	-2.26	-0.67	-0.83	-1.05	-1.98	-4.74	-4.86	-3.73	-2.24
FCF Conversion (FCF/Net Income)	0.94x	0.63x	0.70x	0.83x	0.63x	0.68x	0.62x	0.59x	0.67x
Interest Paid	0	0	0	0	0	22K	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-458.06%	-21.92%	-22.07%	-35.04%	-60.72%	-74.22%	-84.7%
Return on Invested Capital (ROIC)	-	-	-	-55.03%	-157.84%	-379.67%	-93.92%	-69.87%	-130.69%
Debt / Equity	-	-	-	0.01x	0.09x	0.27x	0.43x	0.68x	0.47x
Interest Coverage	-2858.50x	-21.54x	-4.78x	-6148.75x	-5440.28x	-12138.68x	-18965.50x	-21332.38x	-
FCF Conversion	0.94x	0.63x	0.70x	0.83x	0.63x	0.68x	0.62x	0.59x	0.67x

Frequently Asked Questions

Growth & Financials

Kodiak Sciences Inc. (KOD) grew revenue by 0.0% over the past year. Growth has been modest.

Kodiak Sciences Inc. (KOD) reported a net loss of $217.3M for fiscal year 2024.

Dividend & Returns

Kodiak Sciences Inc. (KOD) has a return on equity (ROE) of -84.7%. Negative ROE indicates the company is unprofitable.

Kodiak Sciences Inc. (KOD) had negative free cash flow of $127.3M in fiscal year 2024, likely due to heavy capital investments.